Allogene Therapeutics (ALLO) News Today → Democrats Push to Replace Dollar With Digital Coin, Control Currency. (From Monetary Gold) (Ad) Free ALLO Stock Alerts $2.99 +0.01 (+0.34%) (As of 08:58 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 8:29 AM | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Price Target Cut to $9.00 by Analysts at HC WainwrightHC Wainwright dropped their price objective on Allogene Therapeutics from $10.00 to $9.00 and set a "buy" rating on the stock in a report on Thursday.May 16 at 7:51 AM | marketbeat.comBrokers Issue Forecasts for Allogene Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ALLO)Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Investment analysts at William Blair cut their Q2 2024 earnings per share (EPS) estimates for Allogene Therapeutics in a report issued on Tuesday, May 14th. William Blair analyst S. Corwin now forecasts that the company will post earningsMay 16 at 3:30 AM | americanbankingnews.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) to Post FY2025 Earnings of ($1.98) Per Share, William Blair ForecastsMay 16 at 2:08 AM | americanbankingnews.comAllogene Therapeutics (NASDAQ:ALLO) Trading 9.5% Higher on Analyst UpgradeMay 16 at 2:08 AM | americanbankingnews.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Up 8.0% in AprilMay 15 at 5:23 PM | markets.businessinsider.comBreaking Down Allogene Therapeutics: 5 Analysts Share Their ViewsMay 15 at 3:32 PM | marketbeat.comTruist Financial Reiterates "Buy" Rating for Allogene Therapeutics (NASDAQ:ALLO)Truist Financial reaffirmed a "buy" rating and issued a $17.00 target price on shares of Allogene Therapeutics in a report on Wednesday.May 15 at 10:49 AM | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Stock Price Up 9.5% Following Analyst UpgradeAllogene Therapeutics (NASDAQ:ALLO) Stock Price Up 9.5% Following Analyst UpgradeMay 15 at 9:06 AM | marketbeat.comWilliam Blair Comments on Allogene Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ALLO)Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Stock analysts at William Blair issued their FY2025 earnings estimates for shares of Allogene Therapeutics in a note issued to investors on Tuesday, May 14th. William Blair analyst S. Corwin anticipates that the company will post earningsMay 15 at 6:22 AM | americanbankingnews.comAllogene Therapeutics (NASDAQ:ALLO) Price Target Increased to $4.60 by Analysts at Stifel NicolausMay 15 at 2:02 AM | americanbankingnews.comAllogene Therapeutics (NASDAQ:ALLO) Shares Gap Up Following Analyst UpgradeMay 14 at 11:32 PM | msn.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2024 Earnings Call TranscriptMay 14 at 6:32 PM | markets.businessinsider.comAllogene Therapeutics: Strategic Expansion and Promising Trial Outcomes Bolster Buy RatingMay 14 at 9:32 AM | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Announces Earnings ResultsAllogene Therapeutics (NASDAQ:ALLO - Get Free Report) issued its earnings results on Monday. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.38). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.01 million. Allogene Therapeutics had a negative net margin of 202,366.25% and a negative return on equity of 53.76%. Allogene Therapeutics's revenue was down 26.7% on a year-over-year basis. During the same period last year, the business posted ($0.68) EPS.May 14 at 8:19 AM | marketbeat.comStifel Nicolaus Increases Allogene Therapeutics (NASDAQ:ALLO) Price Target to $4.60Stifel Nicolaus increased their target price on Allogene Therapeutics from $4.40 to $4.60 and gave the company a "hold" rating in a research note on Tuesday.May 14 at 2:46 AM | msn.comAllogene Therapeutics GAAP EPS of -$0.38 beats by $0.03May 14 at 2:46 AM | markets.businessinsider.comAllogene Therapeutics (ALLO) Receives a Buy from TD CowenMay 14 at 2:46 AM | finance.yahoo.comAllogene Therapeutics Reports First Quarter 2024 Financial Results and Business UpdateMay 13 at 9:30 PM | investorplace.comALLO Stock Earnings: Allogene Therapeutics Beats EPS, Beats Revenue for Q1 2024May 13 at 4:47 PM | globenewswire.comAllogene Therapeutics Announces Pricing of $110 million Offering of Common StockMay 13 at 4:01 PM | globenewswire.comAllogene Therapeutics Reports First Quarter 2024 Financial Results and Business UpdateMay 12, 2024 | markets.businessinsider.comAllogene Therapeutics earnings: here's what Wall Street expectsMay 11, 2024 | americanbankingnews.comAllogene Therapeutics (ALLO) to Release Quarterly Earnings on MondayMay 7, 2024 | marketbeat.comAllogene Therapeutics (ALLO) Set to Announce Quarterly Earnings on MondayAllogene Therapeutics (NASDAQ:ALLO) will be releasing earnings after the market closes on Monday, May 13, Zacks reports.May 7, 2024 | americanbankingnews.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of "Moderate Buy" from BrokeragesMay 6, 2024 | globenewswire.comAllogene Therapeutics to Report First Quarter Financial Results and Provide Business UpdateMay 2, 2024 | seekingalpha.comALLO Allogene Therapeutics, Inc.April 29, 2024 | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Stock Price Up 6.6%Allogene Therapeutics (NASDAQ:ALLO) Stock Price Up 6.6%April 26, 2024 | globenewswire.comAllogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell CarcinomaApril 24, 2024 | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Shares Down 3.6% Allogene Therapeutics (NASDAQ:ALLO) Trading Down 3.6%April 20, 2024 | marketbeat.com517,581 Shares in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Bought by Cerity Partners LLCCerity Partners LLC purchased a new position in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 517,581 shares of the company's stock, valuApril 18, 2024 | benzinga.comTo The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation - Allogene Therapeutics (NASDAQ:ALLO), ARK Innovation ETF (ARCA:ARKK)April 15, 2024 | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Stock Price Down 6.1%Allogene Therapeutics (NASDAQ:ALLO) Shares Down 6.1%April 12, 2024 | marketbeat.comVanguard Group Inc. Purchases 3,086,311 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)Vanguard Group Inc. boosted its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 41.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,587,804 shares of the companyApril 12, 2024 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Rating of "Moderate Buy" by BrokeragesShares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight research firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and six have given a buyApril 11, 2024 | investorplace.com3 Meme Stocks to Sell and Replace With Meme CoinsApril 10, 2024 | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Shares Up 2.2%Allogene Therapeutics (NASDAQ:ALLO) Trading 2.2% HigherApril 9, 2024 | globenewswire.comAllogene Therapeutics Announces Q2 Investor Conference ParticipationApril 1, 2024 | seekingalpha.comAllogene Therapeutics: 2024 Platform Vision Sings Mid-Term UpsideMarch 31, 2024 | marketbeat.comZacks Research Weighs in on Allogene Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:ALLO)Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Zacks Research issued their FY2026 EPS estimates for shares of Allogene Therapeutics in a research report issued on Thursday, March 28th. Zacks Research analyst S. Ganoria forecasts that the company will post earnings of ($1.93) per shareMarch 27, 2024 | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Trading 9% Higher Allogene Therapeutics (NASDAQ:ALLO) Stock Price Up 9%March 20, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Their Hold Rating for Allogene Therapeutics (ALLO)March 19, 2024 | markets.businessinsider.comAllogene Therapeutics Poised for Growth: A Strong Buy Rating Amidst Innovative Trials and Strategic AdvancementsMarch 19, 2024 | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Allogene Therapeutics in a research report on Tuesday.March 18, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)March 18, 2024 | marketbeat.comRoyal Bank of Canada Reiterates Outperform Rating for Allogene Therapeutics (NASDAQ:ALLO)Royal Bank of Canada reaffirmed an "outperform" rating and set a $10.00 price target on shares of Allogene Therapeutics in a research report on Friday.March 18, 2024 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAllogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) has been given an average recommendation of "Moderate Buy" by the nine brokerages that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and six have given a buy reMarch 16, 2024 | finance.yahoo.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finanznachrichten.deAllogene Therapeutics, Inc.: Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdateMarch 15, 2024 | markets.businessinsider.comAllogene Therapeutics: Redefining LBCL Treatment with Innovative ALPHA3 Trial and Promising Cema-cel Therapy Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address A ‘DeFi Summer’ Projected! (Ad)Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x! Just click here to learn how you can access this coin right now. ALLO Media Mentions By Week ALLO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALLO News Sentiment▼0.480.54▲Average Medical News Sentiment ALLO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALLO Articles This Week▼333▲ALLO Articles Average Week Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALEC News Today PROK News Today VYGR News Today VALN News Today CCCC News Today EDIT News Today TSHA News Today ADPT News Today HUMA News Today ITOS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALLO) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTop 5 AI Stocks to Buy for 2024Market Moving TrendsDoes this make you sick?Allegiance Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
